Scarica l'app Stockscreener
41.24
0.17%
0.07
Dopo l'orario di chiusura:
41.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$41.17
Aprire:
$41.665
Volume 24 ore:
2.24M
Relative Volume:
0.80
Capitalizzazione di mercato:
$10.71B
Reddito:
$2.29B
Utile/perdita netta:
$677.90M
Rapporto P/E:
17.36
EPS:
2.3753
Flusso di cassa netto:
$779.77M
1 W Prestazione:
-0.73%
1M Prestazione:
-6.10%
6M Prestazione:
+5.34%
1 anno Prestazione:
+12.07%
Intervallo 1D:
$40.55
$41.74
Intervallo di 1 settimana:
$40.52
$42.66
Portata 52W:
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
41.24 | 10.71B | 2.29B | 677.90M | 779.77M | 2.3753 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
EXEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here’s What Makes Exelixis (EXEL) a Top Growth Stock - Bitget
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
EXEL SEC FilingsExelixis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights By Investing.com - Investing.com Canada
EXEL: Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum - TradingView
EXEL: Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets - TradingView
First Trust Advisors LP Has $59.35 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC - Investing.com Canada
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL - MarketBeat
Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL - MarketBeat
What is Zacks Research's Estimate for Exelixis Q3 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
(EXEL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Teton Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Cut to Hold at Zacks Research - MarketBeat
Gainers Report: Will Exelixis Inc benefit from rising consumer demandWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
American Century Companies Inc. Raises Position in Exelixis, Inc. $EXEL - MarketBeat
Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL - MarketBeat
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm
Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st
Exelixis (EXEL) EVP Haley granted 40,459 RSUs vesting from 2027 - Stock Titan
Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan
Exelixis stock falls after rival Merck trial shows better results By Investing.com - Investing.com India
Exelixis stock falls after rival Merck trial shows better results - Investing.com Australia
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus
Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget
Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth With A 7.05% Potential Upside - DirectorsTalk Interviews
Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to Buy - MarketBeat
Exelixis Aims to Expand Beyond Cabozantinib Franchise - Intellectia AI
Exelixis Aims to Become a Top Oncology Player with Expanding Pipeline - Intellectia AI
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - Nasdaq
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - The Motley Fool
Citigroup Inc. Sells 365,552 Shares of Exelixis, Inc. $EXEL - MarketBeat
EXEL PE Ratio & Valuation, Is EXEL Overvalued - Intellectia AI
EXEL Should I Buy - Intellectia AI
Exelixis Director Julie Smith Sells Over 106K Shares - TradingView
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 47,918 Shares - MarketBeat
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):